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ABSTRACT 
Decitabine is a cytidine deoxynucleoside analog, which acts by inhibiting DNA methyltransferase, and is used for the treatment 
of acute myeloid leukemia. Decitabine has a short half-life (25 minutes), and is sensitive to harsh conditions. Elastic liposomes 
are an effective tool that can be used to overcome this disadvantage. Elastic liposomes also known as transfersomes are modified 
lipid carriers that enable drug to reach deeper skin layers and/or the systemic circulation. These vesicular formulations are several 
orders of magnitudes, more deformable than the standard liposomes and thus well suited for skin penetration. The objective of 
present study is to develop and evaluate the elastic liposomes of Decitabine so as to provide the sustained release and improve its 
bioavailability.Elastic liposomes were prepared by rotary evaporation method using Span 80 as a surfactant. The prepared Elastic 
liposomes were evaluated for entrapment efficiency, vesicle size, in vitro drug release. The drug release profiles from different 
elastic liposomes-in-vehicle formulations were in agreement with the physicochemical properties of the formulations. Based on 
different parameters formulations of batch ELS1 was found to be the best formulations. Stability study was performed on the 
selected formulation ELS1. Study concludes that Decitabine can also be formulated in the liposomal carrier which finds its best 
way for the topical administration. 
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Introduction 
At present scenario, the most recent development in vesicle design for transcutaneous bioactive delivery is the use of 
elastic liposomes, which differ from conventional liposomesdue to their characteristic fluid membrane with high 
elasticity
1
. Elastic liposomes have been defined as specially designed vesicular particles, consisting of at least one 
inner aqueous compartment surrounded by a lipid bilayer with appropriately tailored properties. Elastic liposomes 
consist of phospholipids, surfactants such as edge activators, and an inner aqueous compartment enclosed within a 
lipid bilayer capable of encapsulating hydrophilic (in an aqueous chamber) and lipophilic (in a lipid bilayer) 
molecules
2
. 
Drug delivery systems using vesicular carriers have soft, flexible, self-regulating, and self-optimizing vesicular 
characteristics. Greater flexibility of elastic liposomal membranes is achieved by mixing suitable surface-active 
components in the proper ratios
3
. These properties allow them to penetrate more easily into deeper layers of the skin 
and circulation. In Elastic liposomes, elasticity is stress controlled, owing to the composition dependence of the 
membrane bending energy
4
. They are elastic, very deformable vesicles which consist of phosphatidylcholine in 
combination with an edge-active surfactant like sodium cholate and span 80. Elastic liposomes are applied non-
occluded to the skin and are reported to permeate through the stratum corneum lipid lamellar regions as a result of 
the hydration or osmotic force in the skin
5
. Elastic liposomes passage through the normally confining pores is then 
governed by the basic principles of elasto mechanics. However, elastic liposomes resemble lipid vesicles, liposomes, 
in morphology but functionally, elastic liposomes are sufficiently deformable to penetrate pores much smaller than 
their own size. They are metastable, which makes the vesicle membrane ultra flexible and thus the vesicles are 
highly deformable
6
.  
Decitabine is a cytidine deoxynucleoside analog, which acts by inhibiting DNA methyltransferase, inducing DNA 
hypomethylation
7,8
. It is used for the treatmentof acute myeloid leukemia (AML) in patients aged ≥65 years. 
However, it can only be administered intravenously due to very low oral bioavailability and a large distribution 
volume. Decitabine is a hydrophilic drug (log P=−2.2), with a short half-life (25 minutes), and is sensitive to harsh 
conditions
9
.  
Thus the present study was to refine the formulation of elastic liposomes of Decitabine in order to enhance its 
bioavailability. 
 
Materials and methods 
Decitabine was obtained from AC Drugs Limited, Enugu State,  Span 80 and Span 60 were obtained from Afrab-
Chem Limited, Lagos State. Cholesterol was obtained from Asad Pharmaceuticals Ltd, Kano, Nigeria. All other 
chemicals were of analytical grade. 
Preparation of Elastic liposomal formulations 
The Decitabine elastic liposomes were prepared by rotary evaporation method
10
. Different batches of Decitabine 
elastic liposomes were prepared using different proportions of surfactant, phospholipids and drug. The accurately 
weighed amounts of phospholipids and surfactant were taken in a clean, dry, round-bottom flask and this lipid 
mixture was dissolved in small quantity of chloroform-methanol mixture (2:1). The organic solvent was removed by 
rotary evaporation under reduced pressure at 40°C. Final traces of solvents were removed under vacuum overnight. 
The deposited lipid film was hydrated with 7 % v/v ethanol i.e. solution of drug by rotation at 60 rev/min for 1 hr. 
The resulting vesicles were swollen for 2 h at room temperature; these were bath sonicated for 10 min. 
Compositions of different batches of elastic liposomesas shown in Table 1. 
 
 
 
 
Table 1: Compositions of different Decitabine elastic liposomal formulations. 
Formulation 
code 
Decitabine 
(mg) 
Phosphatidylcholine 
(mg) 
Span 80 
(mg) 
Span 60 
(mg) 
Cholesterol 
ELS1 20 80 20 - 30 
ELS2 20 80 20 - 25 
ELS3 20 75 10 10 20 
ELS4 20 70 - 20 18 
ELS5 20 70 - 20 15 
 
 
Drug loading in elastic liposomal formulation 
To determine the maximum amount of drug that can be added in vesicles, increasing amounts of Decitabine (4, 6, 8, 
10 and 12mg) was added during the preparation of elastic liposomal formulations. All the drug loaded vesicular 
formulations were examined for maximum entrapment efficiency and for the appearance of drug crystals over a 
period of 14 days usingoptical microscope
11
. 
 
Characterisation of elastic liposomal formulation 
Particle size analysis 
All the prepared batches of Decitabine elastic liposomes were viewed under microscope to study their size. Size of 
liposomal vesicles from each batch was measured at different location on slide by taking a small drop of liposomal 
dispersion on it and average size of liposomal vesicles were determined
12
. 
Percentage yield of liposomes 
The prepared Decitabine elastic liposomes were collected and weighed. The measured weight was divided by the 
total amount of drug and ingredients which were used for the preparation of the liposomes
13
. 
 
 
Entrapment Efficiency 
For determination of entrapment efficiency the unentrapped drug was separated by the use of the mini column 
centrifugation method. The amount of drug entrapped (Total amt. of drug- unentrapped drug) in the vesicles was 
then determined by disrupting the vesicles using methanol followed by filtration and amount of drug was quantified 
spectrophotometrically
14
. 
 
Redispersibility  
The Decitabine elastic liposomal formulation was centrifuged at 4000 rpm for 18 min at 4 °C 
temperature by using remi cooling centrifuge to separate the free drug. A supernatantcontains the liposomes in 
suspending stage and free drug on the wall of centrifuge tube. The supernatant was again centrifuged at 12000 rpm 
for 38 min at 4 °C temperature. As a result, a transparent solution of supernatant and liposome pellet was attained. 
The pellet was than diluted to 10 ml with deionized water. The solution was then taken in 14 ml Eppendorf tubes 
and vortexed on a vortex mixture at speed 3 for 5 min. After vortexing the solution was then taken in transparent 
cuvettes and particle size was determined after 10 min
15
. 
Zeta potential analysis 
Zeta potential is a physical property which is exhibited by any particle in suspension. It can be used to optimize the 
formulations of suspensions and emulsions. It is also an aid in predicting long-term stability. The magnitude of the 
zeta potential gives an indication of the potential stability of the colloidal system. If all the particles in suspension 
have a large negative or positive zeta potential then they will tend to repeal each other and there will be no tendency 
for the particles to come together.  
A dynamic light scattering instrumentwas used to measure zeta potential of the liposomal formulation. The sample 
was analyzed at 25 °C, using a dispersant refractive index of 1.33. In the current study, the zeta potential of the 
prepared liposomal formulation was measured in disposable folded capillary cells. Samples should be bubble free 
for accurate measurement of zeta potential. Measurement was done with Malvern nano series zeta sizer instrument 
at 25 ºC
16
 
 
Figure 1: Zeta potential distribution of Decitabine elastic liposome of batch ELS1 
 
 
Elasticity Measurement 
For the measurement of elasticity of vesicular membrane, Decitabine elastic liposomal formulations were extruded 
at 2.5 bars through the polycarbonate filter membrane having a pore diameter of 60 to 200 nm using a stainless steel 
pressure holder for 25-mm diameter filters with 200-ml capacity barrel
17
. The elasticity of vesicle membrane was 
calculated by using the following formula -  
 
Where, E = elasticity of vesicle membrane; J = amount of suspension, which was extruded during 10 min; 
rv = vesicles size (after extrusion); and rp = pore size of the barrier 
Table 2: Physicochemical characterization of the Decitabine elastic liposomes 
Code Particle 
size (nm) 
% Entrapment 
efficiency  
%  
Yield  
Zeta Potential 
(Mv) 
Elasticity Redispersion 
(nm) 
ELS1 145 ± 11 70.2 ± 1.3 90.28 -18.4±0.09 28.3±2.6 166 
ELS2 153 ± 12 66.5 ± 2.4 89.43 -16.7±0.16 36.7±3.4 170 
ELS3 165 ± 11 63.3 ± 2.2 88.52 -15.4±0.31 42.8±1.5 159 
ELS4 174 ± 15 55.2 ± 1.5 85.15 -12.5±0.17 54.0±2.6 155 
ELS5 182 ± 13 53.4 ± 2.8 80.34 -13.2±0.26 43.6±1.8 148 
Value represented as mean ± SD (n = 3) 
 
 
In vitro drug release studies through cellophane membrane 
In-vitro drug release studies were carried out in modified Diffusion cell using Dialysis membrane. The membrane 
was soaked in Phosphate buffer pH 6.8 for 9-12 hours and it was clamped carefully to one end of the hollow glass 
tube of dialysis cell (2.3 cm diameter; 4-16 cm
2
 area). Then Decitabine elastic liposomal gel was spread uniformly 
on the dialysis membrane. 50 ml of Phosphate buffer pH 6.8 was taken in a beaker, which was used as receptor 
compartment. The donor compartment was kept in contact with the receptor compartment. This whole assembly was 
kept on a magnetic stirrer and the solution on the receptor side was stirred continuously using a magnetic bead. The 
temperature of the cell was maintained at 37°C. Sample (5 ml) was withdrawn at 1 hour time intervals up to 24 
hours and replaced with equal amounts of fresh dissolution media. Samples were analysed spectrophotometrically at 
260 nm and % cumulative drug release was calculated
18
. 
 
Figure 2: Comparative drug release of all Decitabine elastic liposome formulations 
 
Stability Analysis 
The stability of a pharmaceutical delivery system may be defined as the capability of a particular formulation, in a 
specific container. The behaviour of the Decitabine elastic liposome to retain the drug was studied by storing the 
liposome at 4 different temperature conditions, i.e., 4-8
0
C (refrigerator RF), 25±2
0
C (room temperature RT), 37±2
0
C 
and 45±2
0
C for a period of 1 month. The liposomal preparations were kept in sealed vials. Periodically samples 
were withdrawn and analyzed for the drug content
19
. 
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Figure 3: Stability studies for the Decitabine elastic liposome of batch ELS1 
 
 
Results and discussion 
Different batches of Decitabine elastic liposomes were prepared with Span 80 and Phosphatidylcholine using rotary 
evaporation method.  Span 80 was selected as edge activator surfactant as it is biocompatible and pharmaceutically 
acceptable.  
Phosphatidylcholine was used as bilayer forming agent.  
Decitabine elastic liposomes were evaluated by various parameters like vesicle shape, vesicle size, entrapment 
efficiency, no. of vesicles, in-vitro drug release, ex-vivo skin permeation study, stability study and microbiological 
assay. The particle size distribution of the tested liposomal formulation showed uni-model normal symmetrical 
frequency distribution patterns.  The results of zeta potential for freshly prepared multi lamellar liposomal dispersion 
were given in Table 2 and Figure 1.  
The mean particle diameter of multi lamellar vesicles was found to be in between 145±11 and 182±13 and Zeta 
potential was -12.5±0.17 and -18.4±0.09 respectively.  
The results showed Decitabine elastic liposomes entrapment efficiency was varied with lipid composition and 
cholesterol content. The percentage entrapment efficiency of Decitabine increased with increasing the cholesterol 
content. Formulation ELS1 has shown maximum entrapment efficiency (70.2±1.3). 
Vesicle size distribution is required to check how much % intensity of particles of Elastic liposomes distributed in 
the size range. Vesicle size of optimized ELS1formulation was found to be 145 ± 11nm i.e. in the normal size range 
(1-10,000 nm)
20
. 
Redispersibilty is carried out to check the change in particle size after aggregation. Data suggested from Table 2 
particle size ranges from less than 148nm to 170 nm for all hydration volumes. 
The maximum % release (80.46%±0.47) was shown by formulation of batch ELS1 when compared to all other 
formulations after 9 hrs. The In-vitro drug release studies were given in Figure 2. Cholesterol shows a significant 
effect on drug release studies as the concentration of cholesterol increases the drug release seems to be controlled 
and prolonged.  After evaluating all the parameters the liposomal Formulations were tested for their stability studies 
by subjecting them to different temperatures for a period of one month and were found to be stable with very 
negligible variations.  
The stability studies of the selected Decitabine elastic liposomes formulation ELS1 are shown in Figure 2. There 
were no physical changes observed throughout the study till 30
th
 day at refrigerator temperature.  
The formulation, stored at room temperature, 37
0
C and 45
0
C for 30 days showed varied drug content.  
  
Conclusion 
Elastic liposomes are especially optimizedparticles or vesicles which can provide a novel solution for transport 
related problems.  
Five different Decitabine elastic liposomes formulations were prepared and evaluated for different parameters like 
particle size, % entrapment efficiency, zeta potential, % yield,  elasticity etc. On the basis of different parameters, 
formulations of batch ELS1 were found to be best. The selected elastic liposomes formulations of batch ELS1 
showed good stability profile without any much declination in their properties at different temperature condition for 
a study of 30 days. 
Thus study concludes that Decitabine can also be formulated in the liposomal carrier which finds its best way for the 
topical administration. 
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